Mesenchymal stem cell abnormalities in patients with multiple myeloma

  • La recherche

  • Recherche

01/10/2007

Titre de la revue : Leukemia and Lymphoma Volume : 48 N° : 10 Pagination : 2032-2041 Date de publication : 01/10/2007

Type de document > *Article de revue
Mots clés publication scientifique > cellules souches mésenchymateuses (CSM) , légions des os , myélome , ostéoblaste
Unité de recherche > IRSN/DRPH/SRBE/LTCRA
Auteurs > BOUTIN Laetitia , CHAPEL Alain , DOUCET Christelle , ERNOU Isabelle , GARDERET Laurent , GORIN Norbert Claude , HOLY Xavier , LATAILLADE Jean-Jacques , LOPEZ Manuel , MAZURIER Christelle

Osteolytic bone lesions are common in patients with multiple myeloma (MM), a clonal plasma cell disorder, and result from increased osteoclastic bone resorption and decreased osteoblastic bone formation. Because mesenchymal stem cells (MSCs) are committed towards cells of the osteoblast lineage, we compared the in vitro characteristics of MSCs from the bone marrow of 18 MM patients (MM-MSCs) and eight normal donors (ND-MSCs). MM-MSCs displayed deficient growth that could be explained in part by the reduced expression of several growth factor receptors on the surface of MM-MSCs compared with ND-MSCs. Receptor downregulation was observed on RT-PCR analysis. A major finding was an approximately fivefold higher expression of osteoblast inhibitor DKK1 at transcript and protein levels in MM-MSCs than ND-MSCs. These data suggest that defective osteoblast function in patients with advanced MM may be related not only to factors released by tumor myeloma cells but also to MSC abnormalities.

En savoir plus
Texte complet